Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Inhibition of Angiogenesis by Cleaved High Molecular Weight Kininogen (HKa) and HKa Domain 5

Volume:5   Issue:7
Pp: 519-528
Keith R. McCrae, Fernando Donate, Sergei Merkulov, Danyu Sun, Xiaoping Qi and David E. Shaw
DOI: 10.2174/156800905774574039

Order Reprints Order Eprints

Anti-Angiogenic and Anti-Tumor Properties of Proteasome Inhibitors

Volume:5   Issue:7
Pp: 529-541
Kenyon G. Daniel, Deborah J. Kuhn, Aslamuzzaman Kazi and Q. P. Dou
DOI: 10.2174/156800905774574075

Order Reprints Order Eprints

Control of Copper Status for Cancer Therapy

Volume:5   Issue:7
Pp: 543-549
Vicki L. Goodman, George J. Brewer and Sofia D. Merajver
DOI: 10.2174/156800905774574066

Order Reprints Order Eprints

Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose

Volume:5   Issue:7
Pp: 551-559
Yuval Shaked, Guido Bocci, Raquel Munoz, Shan Man, John M.L. Ebos, Daniel J. Hicklin, Francesco Bertolini, Robert D'Amato and Robert S. Kerbel
DOI: 10.2174/156800905774574020

Order Reprints Order Eprints